October 18, 2022 News by Marisa Wexler, MS MS Therapy EHP-101 Boosts Blood Vessel Growth, Targets Inflammation EHP-101, an experimental treatment being clinically tested for multiple sclerosis (MS), activates a cellular signaling pathway that promotes blood vessel development and reduces inflammation following brain injury, a new study shows. The findings continue to support the use of EHP-101 in MS, a condition marked by excess inflammation and…
January 17, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: Epstein-Barr Virus, EHP-101, Anti-CD20 Therapies, Gut Bacteria Epstein-Barr Virus May be Leading Cause of MS, Raising Risk by 32 Times Several studies over the past few years have suggested a link between the Epstein-Barr virus (EBV) and multiple sclerosis (MS), but this one is huge, both in the number of participants and in the length…
January 14, 2022 News by Yedida Y Bogachkov PhD Trial of Cannabidiol-derived EHP-101 for Relapsing MS Enrolling Soon Emerald Health Pharmaceuticals will soon begin enrollment in a Phase 2a clinical trial investigating its cannabidiol-derived therapy EHP-101 in relapsing forms of multiple sclerosis (MS). The trial (NCT04909502) aims to recruit 50 patients, ages 18-55, with relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).
March 15, 2021 Columns by Ed Tobias MS News That Caught My Eye Last Week: Cure Connections, PIPE-307, Temelimab, EHP-101 NeurologyLive, CMSC Launch Expert Video Series āCure Connectionsā This series of 13 videos, designed for healthcare professionals, focuses on diagnosing MS, its psychological impact, managing symptoms, and treatments. Quality-of-life issues, fatigue, and patient support networks also will be discussed. I hope general neurologists will watch it, not just MS…
March 10, 2021 News by Forest Ray PhD Emerald Health Preparing for Phase 2 Trial of EHP-101 for Relapsing MS Emerald Health Pharmaceuticals (EHP) is preparing for an international Phase 2 clinical trial testing EHP-101 for the treatment of multiple sclerosis (MS). The study will take place in about 20 locations in the U.S. and Australia, and is expected to include approximately 50 patients with relapsing forms of…
March 31, 2020 News by Marisa Wexler, MS Canada Rules EHP-101, Potential Cannabidiol Treatment, Not Controlled Substance EHP-101, a cannabidiol-derived investigational therapy being developed by Emerald Health PharmaceuticalsĀ (EHP)Ā to treat multiple sclerosis (MS), is not a controlled substance in Canada, the company announced. The active ingredient in EHP-101 is a derivative of cannabidiol, abbreviated CBD. This is one of the most well-known active compounds in…
March 3, 2020 News by Marta Figueiredo, PhD #ACTRIMS2020 – EHP-101 Shows Promise in Early Studies; Phase 2 Trial Ahead Emerald Health Pharmaceuticalsā investigational cannabidiol-derived EHP-101 continues to show potential to ease inflammation and myelin loss (demyelination) ā a hallmark of multiple sclerosis (MS) ā according to data from healthy volunteers and a mouse model of MS. The data support the advance of EHP-101’s clinical development into…
August 27, 2019 News by Marisa Wexler, MS Phase 1 Clinical Trial of EHP-101 Concludes with Positive Safety Results The first in-human clinical trial of EHP-101, an investigational treatment for multiple sclerosis (MS) and systemic scleroderma (SSc), has been successfully completed,Ā Emerald Health PharmaceuticalsĀ (EHP) announced. EHP-101 demonstrated it was safe and well-tolerated in healthy volunteers, supporting further clinical development ofĀ EHP-101 in future Phase 2 clinical trials. The…
July 9, 2019 News by Ana Pena PhD Cannabidiol-based Oral Treatment Seen to Promote Remyelination in Mice, Trial Planned in MS Patients EHP-101, a cannabidiol-based experimental therapy for multiple sclerosis, was able to recover myelin in damaged nerve fibers and lessen neuroinflammation in a mouse model of MS, data show. Emerald Health Therapeutics, the manufacturer of EHP-101, also announced plans to open Phase 2 clinical trials in patients by…
April 23, 2019 News by Ana Pena PhD Main Ingredient in Potential MS Therapy EHP-101 Not a Controlled Substance, DEA Rules The U.S. Drug Enforcement Administration (DEA)Ā has determined that theĀ cannabidiol-based active ingredient of EHP-101, an investigational oral treatment for multiple sclerosis (MS)Ā under development by Emerald Health Pharmaceuticals (EHP), should not be classified…
October 1, 2018 News by Diogo Pinto Cannabidiol-derived Treatment for MS, EHP-101, Enters Phase 1 Safety Study, Emerald Health Says Emerald Health PharmaceuticalsĀ announced that it has begun enrolling healthy volunteers for a Phase 1 clinical trial evaluating the safety and tolerability ofĀ EHP-101,Ā a potential cannabidiol treatment for multiple sclerosis (MS) and scleroderma. The randomized, double-blind, and placebo-controlled study (ACTRN12618001390279p) will Ā investigate the safety and pharmacokinetics (how…
August 24, 2018 News by Jose Marques Lopes, PhD Work Showing Potential of EHP-101 in MS Earns Research Award Carmen Navarrete, PhD, has been granted a Scientific Innovation Award for her post-doctoral presentation suggesting that theĀ multiple sclerosisĀ (MS) treatment candidateĀ EHP-101Ā is anti-inflammatory and may boost remyelination,Ā Emerald Health PharmaceuticalsĀ announced. Navarrete, a senior scientist at Vivacell Biotechnology Espana, a company owned by Emerald Health Research, received the award at the…
July 5, 2018 News by Jose Marques Lopes, PhD Cannabidiol Compound, EHP-101, Seen to Prevent Nerve Cell Damage in MS Mouse Model An investigational cannabidiol-derived compound called EHP-101 may help to boost remyelination, prevent nerve cell damage and lower the reactivity of microglia cells ā immune cells of the brain and spinal cord ā a Ā study inĀ mouse models of multiple sclerosis (MS) reports. EHP-101, being developed by Emerald Health…
March 23, 2018 News by Patricia Inacio, PhD Emerald’s Cannabinoid-derived EHP-101 Enhances Remyelination in 2 MS Mouse Models Emerald Health‘sĀ investigational cannabidiol-derived EHP-101 reduces neuroinflammation, the risk of loss of myelin, and nerve cell damage in two mouse models of multiple sclerosis (MS), a new study shows. These results support the potential therapeutic benefits of EHP-101 for MS, and Emerald Health Pharmaceuticals expects to launch a human…